STOCK ALERT: BUY OTC BB : RJVN
The Company profiled below is expected to announce several
major accomplishments via Press Releases, which could
dramatically effect its stock price over the next 30-days.
You can be among the first to receive this information
by opting-in to our mailing list at this time. You will
receive live and timely updates regarding the company
profiled below as well as free trials to valuable
investment tools. See Opt-in instructions below.
Buy OTC BB : RJVN - Investors who are still making money
in the stock market are those who know what stocks are
in play or stocks about to be promoted/syndicated. By
now you probably realize that stocks don't just go up
but are pushed up by brokerage firms that give companies
exposure and analyst coverage, they promote them! To make
money, an investor needs to buy at the beginning of the
PUSH and sell within a 60-day period.
We report on which stocks are being pushed and at what
price levels to buy and sell at. Our current pick, OTC BB :
RJVN is ready to move quickly with news to be released and
a promotion underway.
Company----------RJV Networks, Inc.
52 Week High-----$2.10
52 Week Low------$0.12
Target Price $2 in Q1/2003
Update: Experts agree that RJVN cancer treatment therapies
capable of treating most cancers.
RJVN projects it will be able to treat most cancers with
its combined targeted therapy treatment, which is based
upon an astounding discovery by a molecular biologist at
the Univ. of Michigan - The causal link to breast and most
other malignancies and cancers in the protein Mammastatin.
RJVN has developed a series of cancer treatment therapies,
which utilize pan-cancer market antibodies. Antibody
therapies do not create chemical toxicity and, as such,
are fast tracked through the regulatory approval process.
Using the therapy approach, RJVN is targeted to enter
testing for its products this spring.
RJVN's combination of two leading, well known technologies
previously announced by BioCurex and InNexus Corp along
with RJVN's key MAb protein replicating technology has
allowed the Company to create a series of patented
therapeutic products that many molecular biologists
believe will treat most cancers.
RJVN's R&D and Management are led by Dr. John Todd,
Dr. Charles Morgan (a world renowned molecular biologist
and 5 other industry leading Dr's all with several years
experience in bio-tech development.
For more info see RJVN in the news.
******************* Special Offer *******************
As a member of our opt-in mailing list, you will be
among the first to receive up to the minute information
regarding the company profiled above as well as a free
10-day trial to a website with real-time Level II quotes,
research reports, OTC BB promo / syndication calendar,
trading chat rooms, full threading message boards, along
with many other valuable and free investment tools not
readily available to the general public. This is an
incredible opportunity! Just click the link below to
send us an email, and you will be immediately added to
our Opt-in list. Please be sure that "opt-in" is in the
subject line of the email.
Information within this email contains "forward looking
statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21B of the Securities
Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, goals,
expectations, beliefs, plans, projections, objectives,
assumptions or future events or performance are not
statements of historical fact and may be "forward
Forward looking statements are based on expectations,
estimates and projections at the time the statements
are made that involve a number of risks and uncertainties
which could cause actual results or events to differ
materially from those presently anticipated. Forward
looking statements in this action may be identified
through the use of words such as: "projects", "foresee",
"expects", "estimates," "believes," "understands" "will,"
"anticipates," or that by statements indicating certain
actions "may," "could," or "might" occur. All information
provided within this email pertaining to investing, stocks,
securities must be understood as information provided and
not investment advice. Emerging Equity Alert advises all
readers and subscribers to seek advice from a registered
professional securities representative before deciding to
trade in stocks featured within this email. None of the
material within this report shall be construed as any
kind of investment advice.
In compliance with the Securities Act of 1933,
Section 17(b), Emerging Stock Alert discloses the
receipt of 125,000 unrestricted shares of RJVN from
a third party for the publication of this report. Be
aware of an inherent conflict of interest resulting
from such compensation due to our intent to profit
from the liquidation of these shares. Shares may be
sold at any time, even after positive statements have
been made regarding the above company. All factual
information in this report was gathered from public
sources, including but not limited to SEC filings,
Company Press Releases, and Market Guide. Emerging
Equity Alert believes this information to be reliable
but can make no guarantee as to its accuracy or
completeness. Use of the material within this email
constitutes your acceptance of these terms.
****** Advertising Disclaimer ******
We are an internet advertising company and have received
a monetary payment for this mailing service. We hold no
stocks and have no personal interest in this company
whatsoever. We are simply being paid to perform a service.
This message is an advertisement.
****** Removal Instructions ******
This message has been sent to you in compliance with
our strict anti-abuse regulations. We will continue to
bring you valuable offers on the products and services
that interest you most. If you do not wish to receive
further mailings, please click below. We respect all
removal requests. To be removed immediately from our
mailing lists just click on the link below:
Be sure that "Remove-me" is in the subject line
of the email prior to sending it.
To Unsubscribe: send mail to majordomo(at)de.FreeBSD.org
with "unsubscribe de-bsd-test" in the body of the message
Received on Wed 08 Jan 2003 - 01:45:08 CET